Get the Stockscreener App
24.96
6.55%
-1.75
After Hours:
24.91
-0.05
-0.20%
Moderna Inc stock is traded at $24.96, with a volume of 10.67M.
It is down -6.55% in the last 24 hours and down -6.66% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$26.71
Open:
$26.11
24h Volume:
10.67M
Relative Volume:
0.96
Market Cap:
$9.71B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-2.8591
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
+2.59%
1M Performance:
-6.66%
6M Performance:
-2.08%
1Y Performance:
-40.77%
1-Day Range:
$24.80
$26.20
1-Week Range:
$23.04
$27.10
52-Week Range:
$23.04
$48.92
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
24.96 | 10.44B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.16B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
694.99 | 71.65B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.97 | 59.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.73 | 54.79B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
368.36 | 41.77B | 4.98B | 69.59M | 525.67M | 0.5197 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK - Lohud
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint - York Dispatch
Moderna (MRNA) Shareholders Approve Key Proposals at Special Mee - GuruFocus
Moderna Approves Stock Option Exchange Program - TipRanks
Moderna shareholders approve stock option exchange program for employees By Investing.com - Investing.com South Africa
Moderna (MRNA) Stock Surges Amid Partnership Talks and Strong Q3 Results - GuruFocus
What Is Going On With Moderna Stock? - Forbes
5 Insightful Analyst Questions From Moderna's Q3 Earnings Call - Finviz
CytomX Therapeutics to Present at the Jefferies London Healthcare Conference - GlobeNewswire Inc.
Tobam Purchases 55,542 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025 - Las Cruces Sun-News
How Moderna Inc. stock benefits from tech adoptionPortfolio Growth Summary & Stepwise Trade Execution Plans - newser.com
Day 5 of Gains Streak for Moderna Stock with 13% Return (vs. -36% YTD) [11/12/2025] - Trefis
Carisma Therapeutics Inc. SEC 10-Q Report - TradingView
Moderna Inc. recovery potential after sell offCEO Change & High Return Trade Opportunity Guides - newser.com
Moderna, Inc. Hits New 52-Week Low at USD 23.04 Amid Declining Sales - Markets Mojo
Moderna (MRNA) today — Nov. 12, 2025: Special shareholder vote on option exchange, fresh institutional filings, and live stock action - ts2.tech
Moderna (MRNA) Stock: Top Analyst Reiterates ‘Market Perform’ Rating Amid Cost-Cutting Efforts - CoinCentral
Campbell & CO Investment Adviser LLC Takes Position in Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. $MRNA Stock Position Lowered by Bank of New York Mellon Corp - MarketBeat
Acadian Asset Management LLC Purchases 477,072 Shares of Moderna, Inc. $MRNA - MarketBeat
Gilead Sciences, Moderna, Artivion, Tenet Healthcare, and Charles River Laboratories Stocks Trade Up, What You Need To Know - The Globe and Mail
Moderna (MRNA) News Today—November 11, 2025: UBS Sees 2026 Upside, Redburn Cuts PT to $36, Bernstein Stays Market Perform After Cost Cuts - ts2.tech
Moderna's Cost-Cutting, Pipeline Catalysts Set Stage for 2026 Upside, UBS Says - MarketScreener
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories - The Commercial Appeal
Moderna to Host Investor Event – Analyst Day - The Augusta Chronicle
Moderna (NASDAQ:MRNA) Price Target Cut to $21.00 by Analysts at Bank of America - MarketBeat
Rothschild & Co Redburn Adjusts Price Target on Moderna to $36 From $53, Maintains Neutral Rating - MarketScreener
Q3 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks - The Globe and Mail
Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates - The Marion Star
Is it too late to sell Moderna Inc.2025 Support & Resistance & Stock Market Timing Techniques - newser.com
Moderna (NASDAQ:MRNA) Nasdaq Composite ETF Shapes MedTech Rise - Kalkine Media
B of A Securities Maintains Moderna (MRNA) Underperform Recommendation - Nasdaq
Telemark Asset Management Builds Position in Beaten-Down Biotech Stock. - The Globe and Mail
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Trump administration cancels Moderna contract to fight bird flu and other viruses - news8000.com
What Are Wall Street Analysts’ Target Price for Moderna Stock? - Barchart.com
MRNA: B of A Securities Lowers Price Target Amidst Underperform Rating | MRNA Stock News - GuruFocus
Best Biotech Stocks To ConsiderNovember 6th - MarketBeat
FY2025 EPS Estimates for Moderna Boosted by Analyst - MarketBeat
Moderna to Present at Upcoming Conferences in September 2025 - Sarasota Herald-Tribune
Moderna (MRNA) Is Down 9.6% After Cutting 2025 Sales Outlook and Ending CMV Vaccine Program – Has Sentiment Shifted? - Yahoo Finance
Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism - Central New Jersey News
The Moderna, Inc. (NASDAQ:MRNA) Third-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance
Applying Wyckoff theory to Moderna Inc. stock2025 Momentum Check & Free Expert Verified Stock Movement Alerts - newser.com
Analysts Are Neutral on Top Healthcare Stocks: Neumora Therapeutics, Inc. (NMRA), Moderna (MRNA) - The Globe and Mail
Moderna (NASDAQ:MRNA) Hits New 12-Month Low Following Analyst Downgrade - MarketBeat
Barclays Cuts Moderna (NASDAQ:MRNA) Price Target to $25.00 - MarketBeat
FY2027 EPS Estimate for Moderna Lowered by Analyst - MarketBeat
Moderna Reports Q3 2025 Financial Results - The Globe and Mail
Moderna Inc. (MRNA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
0.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):